A higher percentage of patients treated with an experimental Pfizer Inc drug for osteoporosis died during a clinical trial compared with a placebo, U.S. drug reviewers said in an analysis released on Thursday.
The higher proportion of deaths through five years was statistically significant only for the lowest dose of the drug called Fablyn, said Food and Drug Administration reviewers. More patients given Fablyn, which was co-developed with Ligand Pharmaceuticals Inc, also developed blood clots.
More...
TV News LIES
Establishment News Media...
There is blood on your hands!
1/2 the Story = 1 Complete Lie.
Learn How the Broadcast News
Media Deceive You!
Click Here!
Read The News That "They"
Don't Want You to Notice!
Click Here!
Explore Our Special Coverage
of the Events of 9/11/2001
Click Here!
Sunday, Sep 01st
Last update06:50:01 AM GMT
Headlines